VC
ACRS icon

Vivo Capital’s Aclaris Therapeutics ACRS Stock Holding History

Vivo Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25M Sell
6,666,666
-2,222,222
-25% -$7.5M 2.08% 16
2025
Q4 		$26.8M Hold
8,888,888
– – 1.73% 19
2025
Q3 		$16.9M Hold
8,888,888
– – 1.36% 23
2025
Q2 		$12.6M Hold
8,888,888
– – 1.29% 14
2025
Q1 		$13.6M Hold
8,888,888
– – 1.8% 8
2024
Q4 		$22M Buy
+8,888,888
New +$22.1M 2.47% 7
2023
Q4 		– Sell
-898,631
Closed -$6.16M – 49
2023
Q3 		$6.16M Hold
898,631
– – 0.67% 34
2023
Q2 		$9.32M Hold
898,631
– – 0.64% 25
2023
Q1 		$7.27M Hold
898,631
– – 0.5% 25
2022
Q4 		$14.2M Hold
898,631
– – 1.63% 18
2022
Q3 		$14.1M Hold
898,631
– – 1.56% 20
2022
Q2 		$12.5M Hold
898,631
– – 1.26% 22
2022
Q1 		$15.5M Sell
898,631
-22,351
-2% -$305K 1.07% 22
2021
Q4 		$13.4M Sell
920,982
-19,772
-2% -$300K 0.81% 29
2021
Q3 		$16.9M Sell
940,754
-433,525
-32% -$6.95M 0.76% 26
2021
Q2 		$24.1M Sell
1,374,279
-272,935
-17% -$6.2M 1.04% 23
2021
Q1 		$41.5M Hold
1,647,214
– – 1.46% 15
2020
Q4 		$10.7M Hold
1,647,214
– – 0.48% 39
2020
Q3 		$4.23M Hold
1,647,214
– – 0.24% 54
2020
Q2 		$2.67M Hold
1,647,214
– – 0.19% 51
2020
Q1 		$1.71M Buy
+1,647,214
New +$2.24M 0.16% 48
2019
Q3 		– Sell
-1,647,214
Closed -$3.61M – 6
2019
Q2 		$3.61M Hold
1,647,214
– – 0.34% 38
2019
Q1 		$9.87M Hold
1,647,214
– – 0.98% 26
2018
Q4 		$12.2M Hold
1,647,214
– – 1.55% 18
2018
Q3 		$23.9M Hold
1,647,214
– – 2.41% 15
2018
Q2 		$32.9M Hold
1,647,214
– – 4.24% 5
2018
Q1 		$28.9M Hold
1,647,214
– – 4.09% 7
2017
Q4 		$40.6M Sell
1,647,214
-1,211,355
-42% -$29.5M 8.7% 3
2017
Q3 		$73.8M Hold
2,858,569
– – 14.91% 2
2017
Q2 		$77.5M Hold
2,858,569
– – 19.52% 1
2017
Q1 		$85.2M Sell
2,858,569
-425,000
-13% -$12.3M 25.08% 1
2016
Q4 		$89.1M Sell
3,283,569
-907,828
-22% -$23.1M 29.37% 1
2016
Q3 		$107M Hold
4,191,397
– – 33.45% 1
2016
Q2 		$77.4M Hold
4,191,397
– – 21.14% 2
2016
Q1 		$79.4M Buy
+4,191,397
New +$80.1M 19.92% 1

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vivo Capital's ACRS Position: Q1 2026 in Review

Vivo Capital reduced its Aclaris Therapeutics (ACRS) stake by 25% in Q1 2026, selling an estimated $7.5M and leaving 6,666,666 shares worth $25M. The position accounts for 2.08% of the portfolio, ranked #16.

Vivo Capital first reported a position in ACRS in Q1 2016 and has held it in 35 quarters since. The position peaked at $107M in Q3 2016. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Vivo Capital held 6,666,666 shares of Aclaris Therapeutics worth $25M as of Q1 2026.
  • Vivo Capital sold 2,222,222 Aclaris Therapeutics shares in Q1 2026, an estimated $7.5M.
  • Aclaris Therapeutics made up 2.08% of Vivo Capital's portfolio in Q1 2026, its #16 holding.
  • Vivo Capital first reported a position in Aclaris Therapeutics in Q1 2016 and has held it in 35 quarters since.
  • Vivo Capital's Aclaris Therapeutics position peaked at $107M in Q3 2016.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.